NASDAQ:SCYX SCYNEXIS (SCYX) Stock Price, News & Analysis → Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI Breakthroughs (From InvestorPlace) (Ad) Free SCYX Stock Alerts $2.11 +0.17 (+8.76%) (As of 02:11 PM ET) Add Compare Share Share Today's Range$1.93▼$2.1750-Day Range$1.39▼$1.9452-Week Range$1.35▼$3.87Volume291,566 shsAverage Volume198,607 shsMarket Capitalization$79.72 millionP/E Ratio1.03Dividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get SCYNEXIS alerts: Email Address SCYNEXIS MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside610.9% Upside$15.00 Price TargetShort InterestHealthy2.58% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 15 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.08 to ($0.20) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.11 out of 5 starsMedical Sector297th out of 925 stocksPharmaceutical Preparations Industry130th out of 430 stocks 3.5 Analyst's Opinion Consensus RatingSCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSCYNEXIS has only been the subject of 1 research reports in the past 90 days.Read more about SCYNEXIS's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.58% of the outstanding shares of SCYNEXIS have been sold short.Short Interest Ratio / Days to CoverSCYNEXIS has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in SCYNEXIS has recently decreased by 6.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSCYNEXIS does not currently pay a dividend.Dividend GrowthSCYNEXIS does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SCYX. Previous Next 3.2 News and Social Media Coverage News SentimentSCYNEXIS has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for SCYNEXIS this week, compared to 2 articles on an average week.Search Interest7 people have searched for SCYX on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SCYNEXIS insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.40% of the stock of SCYNEXIS is held by insiders.Percentage Held by Institutions54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about SCYNEXIS's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for SCYNEXIS are expected to decrease in the coming year, from $0.08 to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SCYNEXIS is 1.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.78.Price to Earnings Ratio vs. SectorThe P/E ratio of SCYNEXIS is 1.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 131.29.Price to Book Value per Share RatioSCYNEXIS has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about SCYNEXIS's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceYour Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.Click to watch this device in action About SCYNEXIS Stock (NASDAQ:SCYX)SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.Read More SCYX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCYX Stock News HeadlinesMay 13, 2024 | americanbankingnews.comBrookline Capital Management Research Analysts Lift Earnings Estimates for SCYNEXIS, Inc. (NASDAQ:SCYX)May 12, 2024 | americanbankingnews.comBrookline Capital Management Analysts Raise Earnings Estimates for SCYNEXIS, Inc. (NASDAQ:SCYX)May 13, 2024 | InvestorPlace (Ad)Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.May 10, 2024 | markets.businessinsider.comBuy Recommendation: Scynexis’s Ibrexafungerp Promises Market Breakthrough and Financial GrowthMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal PipelineMay 9, 2024 | investorplace.comSCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | markets.businessinsider.comSCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | finance.yahoo.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 87% over the last five yearsMay 13, 2024 | InvestorPlace (Ad)Your Portfolio’s Shield Against Inflation: Gold’s Surge and AI BreakthroughsWhile gold may be thanking China for its recent growth, this sector is currently thanking Elon Musk. As crazy as it sounds, artificial intelligence just got one step closer to ushering in "the next step in human evolution"... and minting new millionaires. And it's all thanks to Musk's latest AI creation.May 7, 2024 | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) Shares Pass Above Fifty Day Moving Average of $1.56April 30, 2024 | finance.yahoo.comSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)April 20, 2024 | finance.yahoo.comSCYNEXIS, Inc. (SCYX)April 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline ProspectsApril 9, 2024 | globenewswire.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)March 29, 2024 | msn.comSCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023March 28, 2024 | stockhouse.comSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 28, 2024 | globenewswire.comSCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 21, 2024 | benzinga.comSCYNEXIS Stock (NASDAQ:SCYX) Insider TradesFebruary 1, 2024 | markets.businessinsider.comPromising Antifungal Drug Developments Bolster Buy Rating for SCYNEXISJanuary 30, 2024 | finance.yahoo.comSCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology ConferenceJanuary 30, 2024 | finance.yahoo.comSCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis ConferenceJanuary 8, 2024 | stockhouse.comDEADLINE TODAY: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmJanuary 6, 2024 | markets.businessinsider.comScynexis 48 Hour Deadline AlertJanuary 5, 2024 | finance.yahoo.comSCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, ItalyJanuary 1, 2024 | markets.businessinsider.comSCYX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important January 8 Deadline in Securities Class Action - SCYXDecember 29, 2023 | stockhouse.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the FirmDecember 29, 2023 | barrons.comFINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with to Contact the FirmSee More Headlines Receive SCYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SCYNEXIS and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/13/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCYX CUSIPN/A CIK1178253 Webwww.scynexis.com Phone(201) 884-5485Fax201-884-5490Employees29Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+673.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$2.04 Trailing P/E Ratio0.95 Forward P/E Ratio24.25 P/E GrowthN/ANet Income$67.04 million Net Margins72.18% Pretax Margin72.65% Return on Equity112.89% Return on Assets68.17% Debt Debt-to-Equity RatioN/A Current Ratio3.72 Quick Ratio3.72 Sales & Book Value Annual Sales$140.14 million Price / Sales0.52 Cash Flow$1.90 per share Price / Cash Flow1.02 Book Value$1.96 per share Price / Book0.99Miscellaneous Outstanding Shares37,780,000Free Float36,118,000Market Cap$73.29 million OptionableOptionable Beta1.49 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. David Gonzalez Angulo M.D. (Age 59)CEO, President & Director Comp: $631.69kMr. Scott Sukenick J.D. (Age 46)Chief Legal Officer & Corporate Secretary Comp: $542.05kMr. Ivor Macleod CPA (Age 63)M.B.A., Chief Financial Officer Debbie EtchisonExecutive Director of CommunicationsMs. Daniella GiganteVice President of Human Resources & Information TechnologyKey CompetitorsLandos BiopharmaNASDAQ:LABPAssembly BiosciencesNASDAQ:ASMBLantern PharmaNASDAQ:LTRNJourney MedicalNASDAQ:DERMYS BiopharmaNASDAQ:YSView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 129,153 shares on 5/10/2024Ownership: 4.467%Acadian Asset Management LLCBought 21,700 shares on 5/10/2024Ownership: 1.115%AMH Equity LtdBought 109,600 shares on 5/7/2024Ownership: 1.747%Empowered Funds LLCBought 6,650 shares on 5/7/2024Ownership: 0.234%Simplicity Wealth LLCBought 20,000 shares on 4/24/2024Ownership: 0.053%View All Institutional Transactions SCYX Stock Analysis - Frequently Asked Questions Should I buy or sell SCYNEXIS stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYX shares. View SCYX analyst ratings or view top-rated stocks. What is SCYNEXIS's stock price target for 2024? 1 equities research analysts have issued 1-year price objectives for SCYNEXIS's stock. Their SCYX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 610.9% from the stock's current price. View analysts price targets for SCYX or view top-rated stocks among Wall Street analysts. How have SCYX shares performed in 2024? SCYNEXIS's stock was trading at $2.23 at the beginning of the year. Since then, SCYX shares have decreased by 5.4% and is now trading at $2.11. View the best growth stocks for 2024 here. When is SCYNEXIS's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our SCYX earnings forecast. How were SCYNEXIS's earnings last quarter? SCYNEXIS, Inc. (NASDAQ:SCYX) released its earnings results on Thursday, March, 28th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $0.70. The business had revenue of $5.80 million for the quarter, compared to analysts' expectations of $26.14 million. SCYNEXIS had a net margin of 72.18% and a trailing twelve-month return on equity of 112.89%. When did SCYNEXIS's stock split? SCYNEXIS's stock reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of SCYNEXIS own? Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS). Who are SCYNEXIS's major shareholders? SCYNEXIS's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.47%), AMH Equity Ltd (1.75%), Acadian Asset Management LLC (1.11%), Empowered Funds LLC (0.23%) and Simplicity Wealth LLC (0.05%). Insiders that own company stock include Marco Taglietti and Scott Sukenick. View institutional ownership trends. How do I buy shares of SCYNEXIS? Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCYX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDoes this make you sick?Allegiance GoldBill Clinton Backing Biden Replacement???The Freeport SocietyUrgent Nvidia WarningAltimetryThis 1 Biotech Stock has been shocking the marketsHuge AlertsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SCYNEXIS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.